Cargando…

Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy

Background and objectives: EZH2 is overexpressed in hepatocellular carcinoma (HCC) and is correlated with poor prognosis. However, its clinical significance and molecular mechanism have not been studied in HCC. In this study, clinical and prognostic values of EZH2 was studied using Total Cancer Geno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bae, An-Na, Jung, Soo-Jung, Lee, Jae-Ho, Lee, Hyunsu, Park, Seung Gyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877936/ https://www.ncbi.nlm.nih.gov/pubmed/35208478 http://dx.doi.org/10.3390/medicina58020155

Ejemplares similares

EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
por: Wang, Bohan, et al.
Publicado: (2023)

Effects of EZH2 Polymorphisms on Susceptibility to and Pathological Development of Hepatocellular Carcinoma
por: Yu, Yung-Luen, et al.
Publicado: (2013)

EZH2 as a Potential Target for NAFLD Therapy
por: Lim, Hyun Jung, et al.
Publicado: (2020)

The role of EZH1 and EZH2 in development and cancer
por: Lee, Soo Hyun, et al.
Publicado: (2022)

Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma
por: Lee, Hye Won, et al.
Publicado: (2017)

Variation in the Dicer and RAN Genes Are Associated with Survival in Patients with Hepatocellular Carcinoma
por: Kim, Mi Na, et al.
Publicado: (2016)

Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B
por: Shim, Jae-Jun, et al.
Publicado: (2016)

Comprehensive Analysis of NKX3.2 in Liver Hepatocellular Carcinoma by Bigdata
por: Bae, An-Na, et al.
Publicado: (2023)

Muscular axillary arch accompanying variation of the musculocutaneous nerve: axillary arch
por: Jung, Soo-Jung, et al.
Publicado: (2016)

USP7 deubiquitinates and stabilizes EZH2 in prostate cancer cells
por: Lee, Jae Eun, et al.
Publicado: (2020)

The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma
por: Wu, Shi-yi, et al.
Publicado: (2022)

Analysis on EZH2: mechanism identification of related CeRNA and its immunoassay in hepatocellular carcinoma
por: Zhao, Haoran, et al.
Publicado: (2023)

Imaging Findings in a Case of Mixed Acinar-Endocrine Carcinoma of the Pancreas
por: Chung, Won Jung, et al.
Publicado: (2010)

Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma
por: Lee, Jae Seung, et al.
Publicado: (2021)

EZH2 expression in invasive lobular carcinoma of the breast
por: Roh, SiGyun, et al.
Publicado: (2013)

Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma
por: Park, Dong-Jun, et al.
Publicado: (2021)

Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma
por: Xie, Cheng-Rong, et al.
Publicado: (2015)

LINC01419 facilitates hepatocellular carcinoma growth and metastasis through targeting EZH2-regulated RECK
por: Zhang, Gong, et al.
Publicado: (2020)

Clinical Characteristics of TZAP (ZBTB48) in Hepatocellular Carcinomas from Tissue, Cell Line, and TCGA
por: Jung, Soo-Jung, et al.
Publicado: (2022)

USP44 Promotes the Tumorigenesis of Prostate Cancer Cells through EZH2 Protein Stabilization
por: Park, Jae Min, et al.
Publicado: (2019)

MiR-23b-3p suppresses epithelial-mesenchymal transition, migration, and invasion of hepatocellular carcinoma cells by targeting c-MET
por: Park, Na Ri, et al.
Publicado: (2022)

Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor
por: Prawira, Aldo, et al.
Publicado: (2021)

Multiple Bone Metastases as the First Manifestation of Hepatocellular Carcinoma in Patient with Noncirrhotic Liver
por: Bae, Soo Ya, et al.
Publicado: (2015)

MicroRNA-20a Suppresses Tumor Proliferation and Metastasis in Hepatocellular Carcinoma by Directly Targeting EZH1
por: Zhang, Qianqian, et al.
Publicado: (2021)

Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma
por: Sudo, T, et al.
Publicado: (2005)

EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma
por: Guo, Baoping, et al.
Publicado: (2020)

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
por: Xiao, Gang, et al.
Publicado: (2019)

Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging
por: Hwang, Yoon Jung, et al.
Publicado: (2023)

Stereotactic Body Radiotherapy-Induced Arterial Hypervascularity of Non-Tumorous Hepatic Parenchyma in Patients with Hepatocellular Carcinoma: Potential Pitfalls in Tumor Response Evaluation on Multiphase Computed Tomography
por: Park, Mee Jin, et al.
Publicado: (2014)

A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy
por: Oh, Sooyeon, et al.
Publicado: (2020)

Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma
por: Oh, Byong Sun, et al.
Publicado: (2013)

Clinicopathological and Prognostic Characteristics of RAD51 in Colorectal Cancer
por: Lee, Jae-Ho, et al.
Publicado: (2020)

Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma
por: Uebel, Anne, et al.
Publicado: (2023)

Prognostic Value of Different Patterns of Squamous Cell Carcinoma Antigen Level for the Recurrent Cervical Cancer
por: Jeong, Bae Kwon, et al.
Publicado: (2013)

Added Value of Cone-Beam Computed Tomography for Detecting Hepatocellular Carcinomas and Feeding Arteries during Transcatheter Arterial Chemoembolization Focusing on Radiation Exposure
por: Kim, Duk-Ju, et al.
Publicado: (2023)

EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
por: Kusakabe, Yuko, et al.
Publicado: (2021)

EZH2 Expression in Retinoblastoma: A Potential Therapeutic Target
por: Lin, Zhuangling, et al.
Publicado: (2023)

Arginase-1 and P-glycoprotein are downregulated in canine hepatocellular carcinoma
por: Kim, Soo-Hyeon, et al.
Publicado: (2021)

Prognostic value of pretreatment (18)F-FDG PET-CT in radiotherapy for patients with hepatocellular carcinoma
por: Jo, In Young, et al.
Publicado: (2015)

Stereotactic ablative body radiotherapy for spinal metastasis from hepatocellular carcinoma: its oncologic outcomes and risk of vertebral compression fracture
por: Yoo, Gyu Sang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_iapcgs5vumjoetbhab49atdh5o